Boceprevir for untreated chronic HCV genotype 1 infection.

@article{Poordad2011BoceprevirFU,
  title={Boceprevir for untreated chronic HCV genotype 1 infection.},
  author={F. Fred Poordad and Jonathan McCone and Bruce R. Bacon and Savino Bruno and Michael P. Manns and Mark S Sulkowski and Ira M Jacobson and K Rajender Reddy and Zachary D. Goodman and Navdeep Boparai and Mark J Dinubile and Vilma Sniukiene and Clifford A. Brass and Janice K. Adams Albrecht and Jean-Pierre Bronowicki},
  journal={The New England journal of medicine},
  year={2011},
  volume={364 13},
  pages={
          1195-206
        }
}
BACKGROUND Peginterferon-ribavirin therapy is the current standard of care for chronic infection with hepatitis C virus (HCV). The rate of sustained virologic response has been below 50% in cases of HCV genotype 1 infection. Boceprevir, a potent oral HCV-protease inhibitor, has been evaluated as an additional treatment in phase 1 and phase 2 studies. METHODS We conducted a double-blind study in which previously untreated adults with HCV genotype 1 infection were randomly assigned to one of… CONTINUE READING

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 29 CITATIONS

Reply to Harrington et al.

  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2015

References

Publications referenced by this paper.
SHOWING 1-10 OF 19 REFERENCES

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

  • The New England journal of medicine
  • 2002
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL